- Angry questions in Germany after Christmas market attack
- China's Zheng pulls out of season-opening United Cup
- Minorities fear targeted attacks in post-revolution Bangladesh
- Tatum's 43-point triple-double propels Celtics over Bulls
- Tunisia women herb harvesters struggle with drought and heat
- Trump threatens to take back control of Panama Canal
- India's architecture fans guard Mumbai's Art Deco past
- Secretive game developer codes hit 'Balatro' in Canadian prairie province
- Large earthquake hits battered Vanuatu
- Beaten Fury says Usyk got 'Christmas gift' from judges
- First Singaporean golfer at Masters hopes 'not be in awe' of heroes
- Usyk beats Fury in heavyweight championship rematch
- Stellantis backtracks on plan to lay off 1,100 at US Jeep plant
- Atletico snatch late win at Barca to top La Liga
- Australian teen Konstas ready for Indian pace challenge
- Strong quake strikes off battered Vanuatu
- Tiger Woods and son Charlie share halfway lead in family event
- Bath stay out in front in Premiership as Bristol secure record win
- Mahomes shines as NFL-best Chiefs beat Texans to reach 14-1
- Suspect in deadly Christmas market attack railed against Islam, Germany
- MLB legend Henderson, career stolen base leader, dead at 65
- Albania announces shutdown of TikTok for at least a year
- Laboured Napoli take top spot in Serie A
- Schick hits four as Leverkusen close gap to Bayern on sombre weekend
- Calls for more safety measures after Croatia school stabbings
- Jesus double lifts Christmas spirits for five-star Arsenal
- Frankfurt miss chance to close on Bayern as attack victims remembered
- NBA fines Celtics coach Mazzulla and Nets center Claxton
- Banned Russian skater Valieva stars at Moscow ice gala
- Leading try scorer Maqala takes Bayonne past Vannes in Top 14
- Struggling Southampton appoint Juric as new manager
- Villa heap pain on slumping Man City as Forest soar
- Suspect in deadly Christmas market attack railed against Islam and Germany
- At least 32 die in bus accident in southeastern Brazil
- Freed activist Paul Watson vows to 'end whaling worldwide'
- Chinese ship linked to severed Baltic Sea cables sets sail
- Sorrow and fury in German town after Christmas market attack
- Guardiola vows Man City will regain confidence 'sooner or later' after another defeat
- Ukraine drone hits Russian high-rise 1,000km from frontline
- Villa beat Man City to deepen Guardiola's pain
- 'Perfect start' for ski great Vonn on World Cup return
- Germany mourns five killed, hundreds wounded in Christmas market attack
- Odermatt soars to Val Gardena downhill win
- Mbappe's adaptation period over: Real Madrid's Ancelotti
- France's most powerful nuclear reactor finally comes on stream
- Ski great Vonn finishes 14th on World Cup return
- Scholz visits site of deadly Christmas market attack
- Heavyweight foes Usyk, Fury set for titanic rematch
- Drone attack hits Russian city 1,000km from Ukraine frontier
- Former England winger Eastham dies aged 88
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
O.Salvador--PC